Hi-Tech Pharmaceuticals Expands Production Capacity for Phosphagen™ Creatine

Hi-Tech Pharmaceuticals Expands Phosphagen Production to Meet Surging Creatine Demand

Production Scale and Purity Standards

Most commercial creatine products achieve a purity level between 97% and 99%, but Phosphagen™ reaches a 99.99% purity level, according to the source article. This high standard is achieved through a specialized manufacturing method that minimizes common manufacturing impurities such as creatinine and dicyandiamide. To maintain these standards amid rising consumer interest, Hi-Tech Pharmaceuticals is expanding manufacturing capacity across its state-of-the-art facilities located in Norcross and Suwanee, Georgia, as well as State College, Pennsylvania.

Market Growth and Strategic Outlook

The sports nutrition sector has expanded from a niche market for competitive athletes into a mainstream segment for everyday health-conscious consumers. Commenting on the company’s financial and operational trajectory, CEO Jared Wheat stated, “With our current investments, we will achieve significantly profitable growth.”

Diversification Into Emerging Health Research

Creatine research has broadened significantly beyond traditional muscle performance and athletic applications. Modern scientific studies increasingly examine creatine’s potential benefits in areas such as cognitive health, longevity, women’s health, and neuroprotection. These findings have expanded the demographic profile of regular creatine users, prompting companies like Hi-Tech Pharmaceuticals to tailor their marketing and distribution strategies toward a broader wellness audience.